Vancouver, British Columbia / May 28, 2020 – Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to announce that it’s US subsidiary, Advanced Proteome Therapeutics Inc. (“APTI”), has received first results as part of its collaborative pilot project with a promising Boston based biotechnology company (“Biotech”), as announced on February 10, 2020. The pilot project is testing APTI’s site specific conjugation technology with Biotech’s proprietary antibody against a high-value target.

APTIs antibody-drug conjugate (ADC) construct was compared to an ADC construct utilizing the same antibody, toxin and drug to antibody ratio, but alternative conjugation technology. In cell culture studies conducted by Biotech, APTIs ADC demonstrated over 15 times greater potency than the comparator ADC. Based on these results further studies are planned in different models. These further studies are expected to take place upon reopening of the two companies’ laboratories in Boston.

Dr. Benjamin Krantz, Director of APTI commented “This is a fantastic result which shows greater potency of the ADC utilizing APT’s site-specific, homogeneous conjugation technology in this in vitro model. This is particularly exciting because we expect the most significant benefits from APTs ADC conjugation technology to be in vivo, where ADC stability and activity are challenged under physiologic conditions. We look forward to continuing this collaboration and development of this promising ADC.”

Terms of any agreement are to be finalized after pilot completion. The antibody is directed at a highly attractive target that has yet to be successfully addressed. It is overexpressed in up to 90% of malignancies including breast, lung, pancreas, colon and many others. Biotech’s in depth understanding of the target biology has enabled targeting a unique portion that overcomes the limitations of previous strategies. Prior pre-clinical study has demonstrated that both the antibody and target have the appropriate characteristics and therefore substantial promise for ADC therapies. Paul Woodward, CEO of Advanced Proteome Therapeutics Corporation states “This result is another step on the road to proving that APTI’s technology is the gold standard of conjugation technologies, technology that will enable the creation of safer and more efficacious ADC therapeutics for patients.”


Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., has invented proprietary protein conjugation technology which enables the development of superior antibody-drug conjugates through improved site-specific labeling, drug-antibody ratio control and enabling of combination payloads. The technology has compelling pre-clinical data demonstrating improved homogeneity and increased in-vivo potency relative to current state of the art linker technology. The Company believes that the technology will enable the development of safer and more potent antibody-drug conjugate therapeutics and is pursuing licensing and partnership opportunities to advance development and create shareholder value.


Advanced Proteome Therapeutics Corporation
Paul Woodward
President and CEO
Tel: (604)690-3797

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “intends”, “anticipates”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including, without limitation, statements regarding the future plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations are risks detailed from time to time in the filings made by the Company with securities regulators.

Readers are cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that any forward-looking statement will materialize, and readers should not place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will only update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.